BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SCTB41 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SCTB41\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06600022-2178@assetmemo.bio
DTSTAMP:20261121T004533Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:SCTB41: Phase 1/2 readout est. (NCT06600022)
DESCRIPTION:SCTB41\, phase 1/2.\nStudy: Aims to Explore the Safety\, Tolera
 bility\, and Preliminary Efficacy of SCTB41 in Adult Patients with Advance
 d Malignant Solid Tumours.\nEstimated primary completion: 30 April 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/sctb41#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06600022
URL:https://assetmemo.bio/drug/sctb41#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07819188-2178@assetmemo.bio
DTSTAMP:20261121T004533Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:SCTB41: Phase 1/2 readout est. (NCT07819188)
DESCRIPTION:SCTB41\, phase 1/2.\nStudy: SCTB35 and SCTB41 With or Without C
 hemotherapy in Non-Hodgkin Lymphoma\nEstimated primary completion: 30 Sept
 ember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sctb41#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078191
 88
URL:https://assetmemo.bio/drug/sctb41#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07609251-2178@assetmemo.bio
DTSTAMP:20261121T004533Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:SCTB41: Phase 2 readout est. (NCT07609251)
DESCRIPTION:SCTB41\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Clinic
 al Study of SCTB41 Combined With Docetaxel in Patients With Previously Tre
 ated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II 
 Study Ongoing）\nEstimated primary completion: October 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/sctb41#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07609251
URL:https://assetmemo.bio/drug/sctb41#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07594028-2178@assetmemo.bio
DTSTAMP:20261121T004533Z
DTSTART;VALUE=DATE:20290530
DTEND;VALUE=DATE:20290531
SUMMARY:SCTB41: Phase 1/2 readout est. (NCT07594028)
DESCRIPTION:SCTB41\, phase 1/2.\nStudy: Phase I/II Study of SCTB41 Plus SCT
 B39-1with or Without Standard Therapy in Advanced Solid Tumours\nEstimated
  primary completion: 30 May 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/sctb41#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07594028
URL:https://assetmemo.bio/drug/sctb41#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07665970-2178@assetmemo.bio
DTSTAMP:20261121T004533Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:SCTB41: Phase 1/2 readout est. (NCT07665970)
DESCRIPTION:SCTB41\, phase 1/2.\nStudy: SCTB41 Plus SCTB39G With or Without
  Standard Therapy in Advanced Solid Tumors\nEstimated primary completion: 
 30 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sctb41#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0766
 5970
URL:https://assetmemo.bio/drug/sctb41#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662395-2178@assetmemo.bio
DTSTAMP:20261121T004533Z
DTSTART;VALUE=DATE:20300124
DTEND;VALUE=DATE:20300125
SUMMARY:SCTB41: Phase 2/3 readout est. (NCT07662395)
DESCRIPTION:SCTB41\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: SCTB41
  Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cance
 r\nEstimated primary completion: 24 January 2030. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/sctb41#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07662395
URL:https://assetmemo.bio/drug/sctb41#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
